Chemoprevention of Lung Cancer

  • Stéphane Vignot
  • Jean-Philippe Spano
  • Sylvie Lantuejoul
  • Fabrice André
  • Thierry Le Chevalier
  • Jean-Charles Soria
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 166)


Lung cancer remains a major cause of mortality worldwide, despite advances in surgery, radiotherapy and chemotherapy. Most patients present with advanced disease, and early detection approaches are still experimental. Chemoprevention strategies are therefore essential. Chemoprevention can be defined as the use of specific natural or synthetic chemical agents to reverse, suppress or prevent progression to invasive cancer. The present review will provide an update on lung cancer clinical chemoprevention trials as well as the molecular basis of lung carcinogenesis. A better knowledge of lung carcinogenesis is obviously fundamental to improve chemoprevention strategies. Identification of molecular defects involved in premalignant lesions and/or invasive cancer could lead to clinical studies with new molecular-targeted agents (mainly tyrosine kinase inhibitors, farnesyl-transferase inhibitors and/or antiangiogenic molecules) and the development of surrogate biomarkers. Such biomarkers would be essential to detect high-risk patients, select adequate chemoprevention strategies and monitor drug efficacy. New chemoprevention trials are planned with collaborative efforts of researchers involved in fundamental or clinical studies.


Lung Cancer Natl Cancer Inst Small Cell Lung Carcinoma Premalignant Lesion Lung Carcinogenesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156PubMedCrossRefGoogle Scholar
  2. 2.
    Bray F, Sankila R, Ferlay J, Parkin DM (2002) Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38:99–166PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5–26PubMedCrossRefGoogle Scholar
  4. 4.
    Hong WK, Sporn MB (1997) Recent advances in chemoprevention of cancer. Science 278:1073–1077PubMedCrossRefGoogle Scholar
  5. 5.
    Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS, Hittelman WN, Lippman SM, Hong WK (1998) Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 90:1545–1551PubMedCrossRefGoogle Scholar
  6. 6.
    Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus AM, Castegnaro M, Alexandrov K, Rojas M, Saracci R, Giuntini C (1992) Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 98:119–124PubMedGoogle Scholar
  7. 7.
    Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6:963–968PubMedGoogle Scholar
  8. 8.
    Toloza EM, Roth JA, Swisher SG (2000) Molecular events in bronchogenic carcinoma and their implications for therapy. Semin Surg Oncol 18:91–99PubMedCrossRefGoogle Scholar
  9. 9.
    Drakoulis N, Cascorbi I, Brockmoller J, Gross CR, Roots I (1994) Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G) and a T to C mutation in the 3′-flanking region. Clin Investig 72:240–248PubMedCrossRefGoogle Scholar
  10. 10.
    Cheng L, Sturgis EM, Eicher SA, Char D, Spitz MR, Wei Q (1999) Glutathione-S-trans-ferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer 84:220–224PubMedCrossRefGoogle Scholar
  11. 11.
    Jourenkova-Mironova N, Voho A, Bouchardy C, Wikman H, Dayer P, Benhamou S, Hirvonen A (1999) Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer 81:44–48PubMedCrossRefGoogle Scholar
  12. 12.
    Heckbert SR, Weiss NS, Hornung SK, Eaton DL, Motulsky AG (1992) Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst 84:414–422PubMedGoogle Scholar
  13. 13.
    Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, Spitz MR (2000) Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 92:1764–1772PubMedCrossRefGoogle Scholar
  14. 14.
    Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354–1357PubMedGoogle Scholar
  15. 15.
    Sozzi G, Miozzo M, Tagliabue E, Calderone C, Lombardi L, Pilotti S, Pastorino U, Pierotti MA, Della Porta G (1991) Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res 51:400–404PubMedGoogle Scholar
  16. 16.
    Leoncini L, Sforza V, Lavarini E, Nuti S, Gotti G, Tosi P (1988) Flow-cytometric assessment of DNA index and percent S phase cells in bronchogenic epidermoid carcinoma. Appl Pathol 6:28–34PubMedGoogle Scholar
  17. 17.
    Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC, Kemp BL, Khuri FR, Walsh GL, Hittelman WN, Hong WK (1997) Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89:857–862PubMedCrossRefGoogle Scholar
  18. 18.
    Thiberville L, Payne P, Vielkinds J, LeRiche J, Horsman D, Nouvet G, Palcic B, Lam S (1995) Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 55:5133–5139PubMedGoogle Scholar
  19. 19.
    Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, Tolosa E, Armengol P, Barnadas A, Ariza A (1993) Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 8:2407–2412PubMedGoogle Scholar
  20. 20.
    Gosney JR, Field JK, Gosney MA, Lye MD, Spandidos DA, Butt SA (1990) c-myc oncoprotein in bronchial carcinoma: expression in all major morphological types. Anticancer Res 10:623–628PubMedGoogle Scholar
  21. 21.
    Sundaresan V, Reeve JG, Wilson B, Bleehen NM, Watson JV (1991) Flow cytometric and immunohistochemical analysis of p62c-myc oncoprotein in the bronchial epithelium of lung cancer patients. Anticancer Res 11:2111–2116PubMedGoogle Scholar
  22. 22.
    Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL (1993) The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68:162–165PubMedGoogle Scholar
  23. 23.
    Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, Mossetti C, Ardissone F, Lausi P, Scagliotti GV (2004) Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 15:28–32PubMedCrossRefGoogle Scholar
  24. 24.
    Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D, Schwartz DA (1994) C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93:516–520PubMedGoogle Scholar
  25. 25.
    Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H (2000) Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 60:242–244PubMedGoogle Scholar
  26. 26.
    Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L (2000) Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60:4000–4004PubMedGoogle Scholar
  27. 27.
    Mishina T, Dosaka-Akita H, Kinoshita I, Hommura F, Morikawa T, Katoh H, Kawakami Y (1999) Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome. Br J Cancer 80:1289–1295PubMedCrossRefGoogle Scholar
  28. 28.
    Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S, Brambilla C (1999) Alternations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 5:243–250PubMedGoogle Scholar
  29. 29.
    Shriver SP, Bourdeau HA, Gubish CT, Tirpak DL, Davis AL, Luketich JD, Siegfried JM (2000) Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst 92:24–33PubMedCrossRefGoogle Scholar
  30. 30.
    Mao L, El-Naggar AK, Fan YH, Lee JS, Lippman SM, Kayser S, Lotan R, Hong WK (1996) Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res 56:5600–5604PubMedGoogle Scholar
  31. 31.
    Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA, Shay JW (1995) Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 87:895–902PubMedGoogle Scholar
  32. 32.
    Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR (2002) hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res 8:2883–2889PubMedGoogle Scholar
  33. 33.
    Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, Klimstra D, Venkatraman E, Moore MA, Dmitrovsky E (1997) High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 89:1609–1615PubMedCrossRefGoogle Scholar
  34. 34.
    Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW, Gazdar AF (1997) Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res 57:2373–2377PubMedGoogle Scholar
  35. 35.
    Lane DP (1992) Cancer, p53, guardian of the genome. Nature 358:15–16PubMedCrossRefGoogle Scholar
  36. 36.
    Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331PubMedCrossRefGoogle Scholar
  37. 37.
    Takahashi T, Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R (1991) The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6:1775–1778PubMedGoogle Scholar
  38. 38.
    Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T (1992) Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 52:4799–4804PubMedGoogle Scholar
  39. 39.
    Boers JE, ten Velde GP, Thunnissen FB (1996) P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Am J Respir Crit Care Med 153:411–416PubMedGoogle Scholar
  40. 40.
    Brambilla E, Gazzeri S, Lantuejoul S, Coll JL, Moro D, Negoescu A, Brambilla C (1998) p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bc12, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 4:1609–1618PubMedGoogle Scholar
  41. 41.
    Hensel CH, Hsieh CL, Gazdar AF, Johnson BE, Sakaguchi AY, Naylor SL, Lee WH, Lee EY (1990) Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res 50:3067–3072PubMedGoogle Scholar
  42. 42.
    Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C, Slamon DJ (1993) Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 8:1913–1919PubMedGoogle Scholar
  43. 43.
    Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ (1995) Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55:6200–6209PubMedGoogle Scholar
  44. 44.
    Gazzeri S, Gouyer V, Vour’ch C, Brambilla C, Brambilla E (1998) Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 16:497–504PubMedCrossRefGoogle Scholar
  45. 45.
    Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 95:11891–11896PubMedCrossRefGoogle Scholar
  46. 46.
    Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J, Sidransky D (1999) Molecular detection of tumor cells in broncho-alveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91:332–339PubMedCrossRefGoogle Scholar
  47. 47.
    Mao L (1998) Tumor suppressor genes: does FHIT fit? J Natl Cancer Inst 90(6):412–414PubMedCrossRefGoogle Scholar
  48. 48.
    Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G (2002) Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci U S A 99:3615–3620PubMedCrossRefGoogle Scholar
  49. 49.
    Rabbitts P, Douglas J, Daly M, Sundaresan V, Fox B, Haselton P, Wells F, Albertson D, Waters J, Bergh J (1989) Frequency and extent of allelic loss in the short arm of chromosome 3 in nonsmall-cell lung cancer. Genes Chromosomes Cancer 1:95–105PubMedGoogle Scholar
  50. 50.
    Sozzi G, Sard L, De Gregorio L, Marchetti A, Musso K, Buttitta F, Tornielli S, Pellegrini S, Veronese ML, Manenti G, Incarbone M, Chella A, Angeletti CA, Pastorino U, Huebner K, Bevilaqua G, Pilotti S, Croce CM, Pierotti MA (1997) Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57:2121–2123PubMedGoogle Scholar
  51. 51.
    Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, Coll JL (1996) Apoptosis-related factors p53, Bc12, and Bax in neuroendocrine lung tumors. Am J Pathol 149:1941–1952PubMedGoogle Scholar
  52. 52.
    Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY (1993) bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690–694PubMedCrossRefGoogle Scholar
  53. 53.
    Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G (1995) Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71:1003–1007PubMedGoogle Scholar
  54. 54.
    Xu XC, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R (1994) Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 54:3580–3587PubMedGoogle Scholar
  55. 55.
    Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK (1995) Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 332:1405–1410PubMedCrossRefGoogle Scholar
  56. 56.
    Mao EJ, Oda D, Haigh WG, Beckmann AM (1996) Loss of the adenomatous polyposis coli gene and human papillomavirus infection in oral carcinogenesis. Eur J Cancer B Oral Oncol 32B:260–263PubMedGoogle Scholar
  57. 57.
    Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A (1998) Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58:4997–5001PubMedGoogle Scholar
  58. 58.
    Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T (1999) Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5:1001–1005PubMedGoogle Scholar
  59. 59.
    Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105:1589–1594PubMedCrossRefGoogle Scholar
  60. 60.
    Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T (2000) Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6:2006–2011PubMedGoogle Scholar
  61. 61.
    Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338PubMedGoogle Scholar
  62. 62.
    Lippman SM, Benner SE, Hong WK (1994) Cancer chemoprevention. J Clin Oncol 12:851–873PubMedGoogle Scholar
  63. 63.
    Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, et al (1986) 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501–1505PubMedCrossRefGoogle Scholar
  64. 64.
    Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, et al (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795–801PubMedCrossRefGoogle Scholar
  65. 65.
    van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H (2000) EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92:977–986PubMedGoogle Scholar
  66. 66.
    Heimburger DC, Alexander CB, Birch R, Butterworth CE Jr, Bailey WC, Krumdieck CL (1988) Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. JAMA 259:1525–1530PubMedCrossRefGoogle Scholar
  67. 67.
    Lee JS, Lippman SM, Benner SE, Lee JJ, Ro JY, Lukeman JM, Morice RC, Peters EJ, Pang AC, Fritsche HA Jr, et al (1994) Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 12:937–945PubMedGoogle Scholar
  68. 68.
    Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, Rosmentz N, Clerici M, Soresi E, Valente M, et al (1993) Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11:1216–1222PubMedGoogle Scholar
  69. 69.
    [No authors listed] (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. N Engl J Med 330:1029–1035Google Scholar
  70. 70.
    Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150–1155PubMedCrossRefGoogle Scholar
  71. 71.
    Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R (1996) Lack of effect of longterm supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334:1145–1149PubMedCrossRefGoogle Scholar
  72. 72.
    Wang GQ, Dawsey SM, Li JY, Taylor PR, Li B, Blot WJ, Weinstein WM, Liu FS, Lewin KJ, Wang H, et al (1994) Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China. Cancer Epidemiol Biomarkers Prev 3:161–166PubMedGoogle Scholar
  73. 73.
    Wang XD, Liu C, Bronson RT, Smith DE, Krinsky NI, Russell M (1999) Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst 91:60–66PubMedGoogle Scholar
  74. 74.
    Salgo MG, Cueto R, Winston GW, Pryor WA (1999) Beta carotene and its oxidation products have different effects on microsome mediated binding of benzo[a]pyrene to DNA. Free Radic Biol Med 26:162–173PubMedCrossRefGoogle Scholar
  75. 75.
    Paolini M, Cantelli-Forti G, Perocco P, Pedulli GF, Abdel-Rahman SZ, Legator MS (1999) Co-carcinogenic effect of beta-carotene. Nature 398:760–761PubMedCrossRefGoogle Scholar
  76. 76.
    Arnold AM, Browman GP, Levine MN, D’souza T, Johnstone B, Skingley P, Turner-Smith L, Cayco R, Booker L, Newhouse M, et al (1992) The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer 65:737–743PubMedGoogle Scholar
  77. 77.
    Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Broxson A, Lippman SM, Ro JY, Kemp BL, Liu D, Fritsche HA, Xu X, Lotan R, Hong WK (2000) N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 6:2973–2979PubMedGoogle Scholar
  78. 78.
    Kurie JM, Lotan R, Lee JJ, Lee JS, Morice RC, Liu DD, Xu XC, Khuri FR, Ro JY, Hittelman WN, Walsh GL, Roth JA, Minna JD, Hong WK (2003) Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 95:206–214PubMedGoogle Scholar
  79. 79.
    Ayoub J, Jean-Francois R, Cormier Y, Meyer D, Ying Y, Major P, Desjardins C, Bradley WE (1999) Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: implications for chemoprevention of lung cancer. J Clin Oncol 17:3546–3552PubMedGoogle Scholar
  80. 80.
    Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK (2001) Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93:605–618PubMedGoogle Scholar
  81. 81.
    Sun SY, Yue P, Kelloff GJ, Steele VE, Lippman SM, Hong WK, Lotan R (2001) Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. Cancer Epidemiol Biomarkers Prev 10:595–601PubMedGoogle Scholar
  82. 82.
    Dahl AR, Grossi IM, Houchens DP, Scovell LJ, Placke ME, Imondi AR, Stoner GD, De Luca LM, Wang D, Mulshine JL (2000) Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res 6:3015–3024PubMedGoogle Scholar
  83. 83.
    Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Guillaud M, Hawk E, Christen MO, Gazdar AF (2002) A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 94:1001–1009PubMedGoogle Scholar
  84. 84.
    Harris RE, Beebe-Donk J, Schuller HM (2002) Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 9:693–695PubMedGoogle Scholar
  85. 85.
    Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ (1999) Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59:991–994PubMedGoogle Scholar
  86. 86.
    Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, Chamberlain RM, Amos CI, Wan Y, Cinciripini P, Hong WK, Wu X (1998) Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 90:358–363PubMedGoogle Scholar
  87. 87.
    van Poppel G, Kok FJ, Hermus RJ (1992) Beta-carotene supplementation in smokers reduces the frequency of micronuclei in sputum. Br J Cancer 66:1164–1168PubMedGoogle Scholar
  88. 88.
    McLarty JW, Holiday DB, Girard WM, Yanagihara RH, Kummet TD, Greenberg SD (1995) Beta-carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 62(6 Suppl):1431S–1438SGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Stéphane Vignot
    • 1
  • Jean-Philippe Spano
    • 2
  • Sylvie Lantuejoul
    • 3
  • Fabrice André
    • 1
  • Thierry Le Chevalier
    • 1
  • Jean-Charles Soria
    • 1
  1. 1.Department of MedicineInstitut Gustave RoussyVillejuifFrance
  2. 2.Oncology Department, SOMPSHopital La Pitié-Salpetrière AP-HPParisFrance
  3. 3.Cellular Pathology, Lung Cancer Research GroupGrenobleFrance

Personalised recommendations